Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2020
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2017
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2015
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2015
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2014
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2014
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Stress CT Perfusion in Patients With Chest Pain
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2013
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2013
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2013
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2013
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable